Medical Oddities: Dogs share our mortality markers

• by Teraya Smith

• September 2, 2026

FDA clears targeted cholangiocarcinoma therapy

In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.

• by Kathryn Wighton

• September 24, 2026

• 2 min

FDA Clears Home Urine Collection Kit for STI Testing

The clearance enables a validated mail-in workflow for self-collected urine specimens processed on Roche cobas systems.

• by Kathryn Wighton

• June 11, 2026

• 2 min

Can Endotoxin-Targeted Care Improve Sepsis Outcomes?

Biomarker-guided patient selection may help identify patients with sepsis who could benefit from endotoxin-targeted therapy, although confirmatory evidence is still needed.

• by Andrea Surnit

• July 20, 2026

• 3 min